Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
ID: 335885Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/335885

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-329.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)" aimed at supporting research on the long-term adverse effects of cancer therapies. This initiative seeks collaborative projects that investigate the mechanisms behind therapy-induced sequelae, aiming to clinically characterize these effects and develop interventions to prevent or mitigate them. The program emphasizes a multidisciplinary approach and encourages innovative methodologies, with eligible applicants including various educational institutions and organizations, particularly those serving underrepresented communities. Interested parties should note that the application deadline is November 5, 2024, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-21-329-Full-Announcement.html
    PAR-21-329.html
    The funding opportunity from the National Institutes of Health (NIH) aims to support research addressing adverse effects from cancer therapies that can lead to long-term health issues. The initiative focuses on collaborative projects investigating the mechanisms of treatment-induced sequelae to identify their clinical characteristics and develop interventions for prevention and management. Applications can include basic, translational, or clinical studies that either propose clinical trials or not. The announcement specifies eligible applicants and emphasizes a multidisciplinary approach to research. Key research areas include evaluating clinical markers for toxicity, conducting early-phase trials for mitigating strategies, and understanding the progression of acute to chronic adverse effects. The program encourages applicants to utilize innovative methodologies and develop robust data management plans. The maximum project duration is five years, with flexible budget limits based on actual needs. The deadline for applications adheres to standard NIH submission protocols, reinforcing the NIH's commitment to advancing knowledge and improving the quality of life for cancer survivors facing treatment-related challenges.
    Similar Opportunities
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research," aimed at advancing innovative research in biomimetic tissue-engineered technologies for cancer. This initiative seeks to support collaborative, multidisciplinary projects that integrate regenerative medicine, tissue engineering, and cancer biology to develop advanced in vitro and ex vivo models that accurately mimic human cancer pathophysiology. The funding opportunity is crucial for enhancing cancer research methodologies and understanding disease mechanisms, with a maximum budget of $400,000 per year and a project duration of up to five years. Interested applicants must submit their proposals electronically via Grants.gov by May 8, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.
    Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)" aimed at enhancing research on expectancy effects in cancer care. This initiative seeks to explore the mechanisms by which beliefs about treatment outcomes influence cancer symptom management, particularly focusing on historically underrepresented populations to improve health outcomes and reduce disparities. The funding will support clinical trials and experimental projects over a maximum period of five years, with applications due by February 5, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)." This initiative aims to support applications that propose secondary data analysis and integration of existing datasets to better understand cancer risk factors and related outcomes, including survival and treatment responses. The program emphasizes the importance of leveraging clinical, genomic, lifestyle, and environmental data to address significant scientific questions in cancer research. Interested applicants can apply for grants with a maximum budget of $350,000 per year, with a project duration of up to five years. The application deadline is September 7, 2026, and further details can be obtained by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-095.html.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)." This initiative encourages applications that propose innovative secondary data analyses and integration of existing datasets to address significant scientific questions related to cancer risk, prevention, and treatment outcomes. The program aims to leverage diverse data sources, including clinical, environmental, and genomic datasets, to enhance understanding of cancer and improve public health strategies. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and tribal governments, with a maximum funding amount of $200,000 and a project duration of up to two years. Interested parties can find more information and application details at the NIH grants website, with the submission deadline set for September 7, 2026.
    Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)." This initiative aims to support the development of innovative biomimetic tissue-engineered technologies that accurately mimic cancer pathophysiology, facilitating advancements in cancer research and improving diagnostic and treatment strategies. The program encourages collaborative, multidisciplinary projects that integrate regenerative medicine, biomaterials, and bioengineering to create experimental models for studying cancer dynamics. Eligible applicants include a wide range of institutions and organizations, with funding of up to $400,000 in direct costs annually for projects lasting up to five years. Applications are due by May 7, 2025, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-171.html.
    Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Cancer Institute (NCI), is offering a funding opportunity titled "Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers." This initiative aims to support research proposals that develop and test multi-level interventions to improve the quality of transitional care and enhance engagement for over 500,000 U.S. cancer survivors transitioning from pediatric to adult healthcare systems. The program emphasizes addressing health disparities and requires applications to demonstrate scalability and sustainability of proposed interventions, fostering effective communication between patients and providers. The total funding available is approximately $10 million, with a maximum annual budget cap of $499,000 per project over a five-year period. Interested applicants must submit their proposals by October 18, 2025, with projects expected to commence in March 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-019.html.
    Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)." This initiative aims to establish population-based cancer epidemiology cohorts to address critical knowledge gaps in cancer etiology and survivorship, particularly focusing on engaging diverse and underserved populations. The project will support methodological work necessary for cohort development, emphasizing community engagement and the validation of cancer outcomes linked to population-based registries. Interested applicants, including educational institutions, nonprofits, and local governments, must submit their proposals by February 28, 2025, and can find additional details at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.